Crohn's Disease
Conditions
Interventions
Observation Group of the Effect of Infliximab in Treating Crohn's Disease:None
Sponsors
The Second Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. Diagnosed with Crohn's disease (according to Chinese guidelines); 3. First use of infliximab (IFX) for the treatment of active ulcerative colitis (UC); 4. Has baseline and endpoint assessment data, or has experienced a clear failure of treatment; 5. Complete IFX administration information is available.
Exclusion criteria
Exclusion criteria: 1. IFX is used for non-active cavity-type CD indications (such as isolated perianal lesions, postoperative prevention); 2. Has previously used any biologic agents or JAK inhibitors; 3. Interrupted induction therapy due to non-efficacy reasons (such as infection, adverse reactions, compliance); 4. There is a serious lack of key baseline data; 5. The outcome cannot be clearly attributed to the insufficient efficacy of IFX.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response rate;Primary non-response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoscopic response rate;CRP normalization rate; | — |
Countries
China
Contacts
Public ContactBaisui Feng
The Second Affiliated Hospital of Zhengzhou University
Outcome results
None listed